Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, and how safe it is in participants with metastatic cancer (cancer that has spread).
Metastatic Solid Tumor
DRUG: Sacituzumab Govitecan-hiy
Percentage of Participants Experiencing any Adverse Events, First dose date up to last dose date plus 30 days (approximately 3 years)|Percentage of Participants Experiencing any Serious Adverse Events, First dose date up to last dose date plus 30 days (approximately 3 years)|Percentage of Participants Experiencing Laboratory Abnormalities, The percentage of participants experiencing any clinically significant laboratory abnormality will be summarized., First dose date up to last dose date plus 30 days (approximately 3 years)
This is a rollover study. Only participants who continue to receive clinical benefit from continuation of sacituzumab govitecan-hziy therapy and are tolerating therapy at the time of enrollment are eligible for this study. Participants enrolled may continue to receive sacituzumab govitecan-hziy at the dose that they were receiving in the Gilead parent study at the time of consenting to participate in this rollover study.